PLCB1 and neoplasm: For instance, targeting PI-PLC-mediated EV signaling in osteosarcoma could disrupt tumor–microenvironment interactions, while modulating PI-PLCβ4 activity might mitigate excessive osteoclast activation in osteoporosis.